Literature DB >> 1537889

Glycolipid depletion using a ceramide analogue (PDMP) alters growth, adhesion, and membrane lipid organization in human A431 cells.

S Barbour1, M Edidin, B Felding-Habermann, J Taylor-Norton, N S Radin, B A Fenderson.   

Abstract

Glycolipids were depleted from the membranes of human A431 cells using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), an inhibitor of glucosylceramide synthetase. After 6 days of culture in the presence of 5 microM D-threo-PDMP, glycolipid content was reduced to approximately 5% of control levels. By contrast, synthesis per cell of phosphatidylcholine, sphingomyelin, triglycerides, and glycoprotein was relatively unchanged in PDMP-treated cells. In parallel with glycolipid depletion, PDMP-treated cells exhibited a rapid loss of epithelial cell morphology, a reduced rate of cell growth, and inhibition of cell-substrate adhesion. The effects of D-threo-PDMP on cell morphology and substrate adhesion were blocked by exogenous GM3 addition and were not observed with L-threo-PDMP (a relatively inactive enantiomer). Fluorescence photobleaching and recovery (FPR) was used to investigate the hypothesis that glycolipids influence cell behavior, in part, by changing the diffusion characteristics of membrane proteins and lipids. Diffusion coefficients and mobile fractions of two integral membrane proteins, the EGF receptor and a class I MHC antigen, did not differ significantly between control and PDMP-treated cells. Diffusion coefficients of lipid probes, NBD-PC and fluorescent GM1 ganglioside, were similarly unaffected by glycolipid depletion. However, lipid probes did show a significant increase in mobile fraction (the fraction of lipids that are free to diffuse) in PDMP-treated cells. This increase was blocked by culturing cells in the presence of exogenous GM3 ganglioside. The results suggest that glycolipids play a role in the formation of lipid domains in A431 cell membranes. Glycolipid-mediated changes in membrane lipid organization may influence receptor activation and transmembrane signaling, leading to changes in cell growth, morphology, and adhesion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1537889     DOI: 10.1002/jcp.1041500322

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  Importance of glycolipid synthesis for butyric acid-induced sensitization to shiga toxin and intracellular sorting of toxin in A431 cells.

Authors:  K Sandvig; O Garred; A van Helvoort; G van Meer; B van Deurs
Journal:  Mol Biol Cell       Date:  1996-09       Impact factor: 4.138

2.  Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion.

Authors:  A E Bielawska; J P Shapiro; L Jiang; H S Melkonyan; C Piot; C L Wolfe; L D Tomei; Y A Hannun; S R Umansky
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

3.  Ceramide structure predicts tumor ganglioside immunosuppressive activity.

Authors:  S Ladisch; R Li; E Olson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

4.  Differential effects of three inhibitors of glycosphingolipid biosynthesis on neuronal differentiation of embryonal carcinoma stem cells.

Authors:  Sean S Liour; Robert K Yu
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

5.  Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): attenuation of C(18)-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis.

Authors:  Serdar Karahatay; Kesha Thomas; Serap Koybasi; Can E Senkal; Saeed Elojeimy; Xiang Liu; Jacek Bielawski; Terry A Day; M Boyd Gillespie; Debajyoti Sinha; James S Norris; Yusuf A Hannun; Besim Ogretmen
Journal:  Cancer Lett       Date:  2007-07-09       Impact factor: 8.679

6.  A mouse B16 melanoma mutant deficient in glycolipids.

Authors:  S Ichikawa; N Nakajo; H Sakiyama; Y Hirabayashi
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

Review 7.  Protection against Shiga Toxins.

Authors:  Simona Kavaliauskiene; Anne Berit Dyve Lingelem; Tore Skotland; Kirsten Sandvig
Journal:  Toxins (Basel)       Date:  2017-02-03       Impact factor: 4.546

8.  Review of miglustat for clinical management in Gaucher disease type 1.

Authors:  Can Ficicioglu
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.